STERIS plc

(New York Stock Exchange)
Back to all articles
Bullish +62

STERIS Announces Financial Results for Fiscal 2027 First Quarter

AI-generated analysis

πŸ“ˆ Total revenue increased 7% year-over-year to $1.5 billion, with constant currency organic growth of 6%.

πŸ’° Adjusted diluted EPS rose to $2.59 per share, up from $2.34 in the prior year period.

πŸ₯ Healthcare segment revenue grew 8% to $1.05 billion, driven by 10% service and 9% consumable growth.

πŸ”¬ Life Sciences revenue increased 9% to $146.7 million, led by a 17% surge in capital equipment sales.

🏭 Applied Sterilization Technologies (AST) revenue grew 6% to $297.6 million despite a 13% drop in capital equipment.

πŸ”„ A restructuring plan was announced to consolidate formulated chemistries manufacturing into a new North Carolina Center of Excellence.

πŸ’Έ The company expects pre-tax restructuring charges of $55 million to $70 million, including $40-50 million in cash costs.

πŸ—οΈ Capital expenditure guidance was raised to approximately $450 million due to the new manufacturing investment.

πŸ“‰ Free cash flow decreased to $279.6 million for the quarter, primarily due to lower working capital contributions.

🎯 Management reiterated full-year guidance with as-reported revenue growth of 7-8% and adjusted EPS of $11.10-$11.30.

Bullish Signals
  • Total revenue grew 7% year-over-year to $1.5 billion, demonstrating resilient top-line performance.
  • Adjusted diluted EPS increased to $2.59, beating market expectations and showing improved profitability.
  • Healthcare segment revenue surged 8% to $1.05 billion, driven by strong double-digit growth in high-margin consumables and services.
  • Life Sciences capital equipment revenue jumped 17%, indicating robust demand for the company's sterilization technology solutions.
  • The company successfully maintained its full-year revenue and earnings guidance despite macroeconomic headwinds.
  • Operating income expanded across all segments due to favorable mix, volume improvements, and price increases.
Risk Factors
  • Free cash flow declined to $279.6 million from $326.5 million in the prior year quarter.
  • The restructuring plan will incur significant pre-tax charges of $55 million to $70 million over time.
  • Capital expenditures are being increased to $450 million, which is higher than the previous guidance of $375 million.
  • Applied Sterilization Technologies (AST) capital equipment revenue fell 13%, offsetting some service growth.
  • Inflation and increased tariff costs partially offset gains in operating income across segments.
Full Analysis
STERIS plc reported strong financial results for its fiscal 2027 first quarter ended June 30, 2026. Total revenue increased 7% year-over-year to $1.5 billion, driven by a 6% constant currency organic growth rate. Adjusted diluted earnings per share rose to $2.59, reflecting improved operational performance across its core segments. The company's Healthcare segment led the growth with an 8% revenue increase to $1.05 billion, fueled by double-digit gains in service and consumable revenues. Applied Sterilization Technologies (AST) saw a 6% revenue rise, while Life Sciences grew 9%, primarily driven by capital equipment sales. Operating income expanded across all segments due to volume and price improvements. STERIS announced a targeted restructuring plan to consolidate its formulated chemistries manufacturing into a new Center of Excellence in North Carolina. This initiative involves closing facilities in St. Louis and Plymouth, with expected pre-tax charges between $55 million and $70 million over time. Consequently, the company raised its full-year capital expenditure guidance to approximately $450 million. Despite the restructuring costs and increased capex, STERIS maintained its full-year revenue and earnings guidance. The company reiterated expectations for as-reported revenue growth of 7-8% and adjusted EPS between $11.10 and $11.30. Management highlighted stable underlying demand and continued share gains in consumables as key drivers for navigating the complex operating environment.